Surgery vs. Chemoradiotherapy for Esophageal Cancer

Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

Recruiting Phase 3 Interventional Study
Esophageal Squamous Cell Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,044 (estimated)
Sponsor
Henan Cancer Hospital · Government
Who this trial is looking for

This trial is looking for adults with esophageal cancer who have had some initial treatment and responded well. Participants will either have surgery or receive a combination of chemotherapy and radiation.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 18 and 75 years old.
  • I have a good performance status.
  • I have been diagnosed with thoracic esophageal squamous cell carcinoma.
  • My cancer is at a certain stage that can be surgically removed.
  • I have adequate bone marrow, liver, and kidney function.
  • I have signed a consent form to take part.

You may not be able to join if

  • I have had another cancer in the past 5 years.
  • I have an active autoimmune disease.
  • I have active Hepatitis B or C, or HIV.
  • I have severe heart or lung problems.
  • I am pregnant or breastfeeding.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell carcinoma (ESCC) who achieve a complete or partial clinical response (cCR/cPR) following neoadjuvant immunochemotherapy.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years, any sex. 2. ECOG Performance Status 0-1. 3. Histologically confirmed, previously untreated thoracic esophageal squamous cell carcinoma (ESCC). 4. Clinical stage cT2N0M0, T3N0-2M0 (AJCC 8th Edition), assessed as resectable with a potential for R0 resection by …
Contacts

Yan Zheng, M.D./Ph.D

(+86)0371-65587610

hnszlyylixiang@163.com

CONTACT

Song

(+86)0371-65587610

hnszlyylixiang@163.com

CONTACT